Replies to post #796405 on NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

skitahoe,

The science is getting to the point where biomarkers and disease state will determine the proper course of action without much guessing. I believe that the IFR funding pathway is now kind of being used as the beginning of this kind of focused and personalized treatment intervention. The early info obviously came from the Phase 3 L trial, other combo trials and Specials Program patients. What happens next seems to be real world data gathering from specific treatment regimens being agreed to based on likelihood of need and response. If this is what happens then cancer treatment will be looking quite different in the not too distant future and your experience at City of Hope will look more like the norm than the outlier with the exception that there won’t be as much guessing. That will be mostly replaced with a series of normalized steps; ). Best wishes.

[DocLee]

Hi, Gary. The SOC ("Standard of Care") is essentially a guide as to the best way to treat a medical condition. It is not a legal document but in the UK (I cannot speak for the US) it is expected that doctors will follow the guidelines as this will give them a degree of protection if all does not go well for the patient. In those instances if doctors do not follow the guidelines competently they could be exposed to the criticism of not having treated patients correctly. In essence, doctors then have to prove their innocence rather than innocence being assumed. In the UK the guidelines are essentially set by the various professional bodies (such as the Royal College of Physicians, Surgeons, Obstetricians et al ) and are recognised as such by the General Medical Council (the regulatory body which licences medical practitioners to work in the UK), the legal profession and medical insurers.

The SOCs are not set in stone so the answer to your question is a simple, "Yes, DCVax-L could be added to the SOC without further ado, with (if the clinical evidence is already sufficiently strong) pre-treatment with poly-ICLC followed by pembrolizumab also being added". For a more radical changes such as the removal of temozolomide, a controlled trial would almost certainly be needed to ascertain whether removal resulted in increased or decreased survival.

Best wishes.